8-K: Aptevo Therapeutics Appoints Baker Tilly as New Auditor Amidst Going Concern Uncertainty

Aptevo Therapeutics Inc. announced the appointment of Baker Tilly US, LLP as its new independent registered public accounting firm, effective June 23, 2025, following the merger of its previous auditor, Moss Adams LLP, with Baker Tilly, though prior audit reports included a going concern uncertainty.

Summary

• Aptevo Therapeutics Inc. (the "Company") has changed its independent registered public accounting firm.
• Moss Adams LLP, the Company's previous auditor, merged with Baker Tilly US, LLP on June 3, 2025.
• As a result of the merger, Moss Adams resigned, and Baker Tilly was appointed as the successor auditor for the year ending December 31, 2025, effective June 23, 2025.
• Moss Adams' audit reports on the Company's consolidated financial statements for the years ended December 31, 2024, and 2023, contained an explanatory paragraph regarding a "going concern uncertainty."
• There were no disagreements with Moss Adams on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure during the years ended December 31, 2024 and 2023, and the subsequent interim period through June 23, 2025.
• No reportable events requiring disclosure pursuant to Item 304(a)(1)(v) of Regulation S-K occurred during the specified periods.
• The Company did not consult with Baker Tilly regarding the application of accounting principles or the type of audit opinion prior to their appointment.

Sentiment

Score: 3

Explanation: While the auditor change was a smooth transition due to a merger and not due to disagreements, the persistent 'going concern uncertainty' noted in the audit reports for 2023 and 2024 is a significant negative indicator of the company's financial health and future viability.

Positives

• The change in auditor was a result of a merger between the previous firm and Baker Tilly, rather than due to any disagreements or reportable events with the Company, indicating a smooth procedural transition.
• Moss Adams LLP confirmed its agreement with the statements made by Aptevo Therapeutics Inc. in the Form 8-K, demonstrating transparency and adherence to regulatory requirements.

Negatives

• Moss Adams' audit reports for the fiscal years ended December 31, 2024, and 2023, included an explanatory paragraph regarding a "going concern uncertainty," which indicates substantial doubt about the Company's ability to continue as a going concern.

Risks

• The primary risk is the "going concern uncertainty" noted in the audit reports for the years ended December 31, 2024, and 2023, which raises significant questions about the Company's financial viability and ability to meet its obligations in the foreseeable future.

Future Outlook

The document does not provide specific forward-looking statements or guidance beyond the appointment of a new auditor for the fiscal year ending December 31, 2025.

Management Comments

• The Company provided Moss Adams with a copy of this Current Report on Form 8-K prior to its filing with the Securities and Exchange Commission and requested that Moss Adams furnish the Company with a letter addressed to the Commission stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree.

Industry Context

This change in auditor is a routine corporate governance event, often triggered by mergers or acquisitions within the accounting industry. For biotechnology companies like Aptevo, maintaining a stable and reputable auditing firm is crucial for investor confidence, especially given the inherent risks and capital intensity of the sector. The 'going concern' note, however, places Aptevo in a more challenging position compared to financially stable peers within the biotech industry.

Comparison to Industry Standards

• The transition of auditors due to a merger of accounting firms is a standard practice and does not inherently signal issues with the company's financial reporting, aligning with industry norms for such events.
• The presence of a 'going concern uncertainty' in audit reports for two consecutive years (2023 and 2024) is a significant deviation from the standard for healthy, publicly traded companies and is a red flag that warrants close scrutiny by investors, unlike many established biotech firms that demonstrate clear paths to profitability or sufficient cash runways.

Corporate Governance

Stakeholder Impact

• Shareholders: The 'going concern uncertainty' raises significant concerns about the long-term viability of their investment and potential for dilution or loss of capital. The smooth auditor transition, however, maintains confidence in financial reporting integrity.
• Creditors: The 'going concern uncertainty' could impact the company's ability to secure new financing or maintain existing credit lines, potentially leading to stricter terms or higher interest rates.
• Employees: While not directly stated, a 'going concern uncertainty' can create instability and uncertainty regarding job security and future prospects.

Next Steps

• Baker Tilly US, LLP will serve as the independent registered public accounting firm for the year ending December 31, 2025.

Key Dates

Recommendation

Keywords

Aptevo Therapeutics, APVO, SEC filing, 8-K, auditor change, Moss Adams, Baker Tilly, accounting firm, going concern, financial reporting, corporate governance